Sign up online today & collaborate
or click here to find out more
A vaccine created by Novavax has become the first to show efficacy in protecting again the ultra common respiratory syncytial virus, a major respiratory pathogen in infants, children, and adults around the globe.
Data from a Phase II trial of the jab show statistically significant efficacy in the prevention of all symptomatic RSV disease (44%) and RSV disease with symptoms of lower respiratory tract infection (46%) in older adults.
For more click here